XFXinglong Fan

Xinglong Fan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinglong Fan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Cuixia Chen

    State Key Laboratory of Heavy Oil Processing and Center for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China

    4 shared publications
  • Qilong Gu

    State Key Laboratory of Heavy Oil Processing and Center for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China

    3 shared publications
  • Hai Xu

    State Key Laboratory of Heavy Oil Processing and Centre for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China

    2 shared publications
  • Tiantian Liang

    State Key Laboratory of Heavy Oil Processing and Centre for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China

    2 shared publications
  • Chao Sun

    Department of Clinical Translational Medicine, YuceBio Technology Co., Ltd., Shenzhen 518000, China

    1 shared publication
  • Chen Wang

    State Key Laboratory of Heavy Oil Processing and Centre for Bioengineering and Biotechnology, China University of Petroleum (East China), 66 Changjiang West Road, Qingdao 266580, China

    1 shared publication

Latest Publications

  • Glycine linker modulates the tunable self-assembly and antibacterial efficacy of octanoyl lipopeptides

    by Cuixia Chen, Yiyi Zhang, Qilong Gu, Chi Gu, Xiaoyang Zhang, Xiaofang Jiang, Ximeng Song, Xinglong Fan


  • Antibiofilm Mechanisms of the Helical G3 Peptide against Staphylococcus epidermidis

    by Cuixia Chen, Qilong Gu, Yangyang Ge, Jingyun Tian, Yusen Zhang, Tianling Wang, Chen Wang, Yurong Zhao, Hai Xu, Xinglong Fan

    Antibacterial peptides (ABPs) have been recognized as promising alternatives to conventional antibiotics due to their broad antibacterial spectrum, high antibacterial activity, and low possibility of inducing bacterial resistance. However, their antibiofilm mechanisms have not yet reached a consensus. In this study, we investigated the antibiofilm activity of a short helical peptide G3 against Staphylococcus epidermidis, one of the most important strains of medical device contamination. Studies show that G3 inhibits S. epidermidis biofilm formation in a variety of ways. In the initial adhesion stage, G3 changes the properties of bacterial surfaces, such as charges, hydrophobicity, and permeability, by rapidly binding to them, thus interfering with their initial adhesion. In the mature stage, G3 prefers to target extracellular polysaccharides, leading to the death of outside bacteria and the disruption of the three-dimensional (3D) architecture of the bacterial biofilm. Such efficient antibiofilm activity of G3 endows it with great potential in the treatment of infections induced by the S. epidermidis biofilm.


  • Disassembling ability of lipopeptide promotes the antibacterial activity

    by Liuxin Yang, Cuixia Chen, Tiantian Liang, Liyun Hao, Qilong Gu, Hai Xu, Yurong Zhao, Lixia Jiang, Xinglong Fan


  • Amyloid-like aggregates of short self-assembly peptide selectively induce melanoma cell apoptosis

    by Xiaoting Peng, Jiachen Hao, Wenwen Tao, Diange Guo, Tiantian Liang, Xuelei Hu, Hai Xu, Xinglong Fan, Cuixia Chen


  • Open Access

    Genomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma

    by Yaobo Song, Zhen Qu, Hu Feng, Long Xu, Yajie Xiao, Zhikun Zhao, Dongfang Wu, Chao Sun, Xinglong Fan, Dongmei Zhou

    Pyroptosis is a programmed cell death that may either promote or hinder cancer growth under different circumstances. Pyroptosis-related genes (PRGs) could be a useful target for cancer therapy, and are uncommon in lung adenocarcinoma (LUAD). The expression profiles, mutation data and clinical information of LUAD patients were included in this study. A pyroptosis-related prognostic risk score (PPRS) model was constructed by performing Cox regression, weighted gene co-expression network analysis (WGCNA), and least absolute shrinkage and selection operator (LASSO) analysis to score LUAD patients. Somatic mutation and copy number variation (CNV), tumor immunity, and sensitivity to immunotherapy/chemotherapy were compared between different PPRS groups. Clinical parameters of LUAD were combined with PPRS to construct a decision tree and nomogram. Red module was highly positively correlated with pyroptosis. Seven genes (FCRLB, COTL1, GNG10, CASP4, DOK1, CCR2, and AQP8) were screened from the red module to construct a PPRS model. Significantly lower overall survival (OS), higher incidence of somatic mutation and CNV, elevated infiltration level of the immune cell together with increased probability of immune escape were observed in LUAD patients with higher PPRS, and were more sensitive to Cisplatin, Docetaxel, and Vinorelbine. We constructed a new PPRS model for patients with LUAD. The model might have clinical significance in the prediction of the prognosis of patients with LUAD and in the efficacy of chemotherapy and immunotherapy.


  • Open Access

    Postoperative Adjuvant Treatment Options in Resected Non–Small-Cell Lung Cancer

    by Qiuyu Hou, Ningning Luo, Mengmeng Li, Yingxue Qi, Xinglong Fan

    Lung cancer remains the most common malignancies and the leading cause of mortality worldwide, more than 80% of which are Non–Small-Cell Lung Cancer (NSCLC). For approximately one-third of diagnosed NSCLCs with stage I–IIIA disease, surgical resection is recommended as a preferred curative treatment. Nevertheless, many resected NSCLC patients experience recurrence. The adjuvant treatment option of patients with resected Non–Small-Cell Lung Cancer (NSCLC) remains unstandardized. At present, there are many postoperative adjuvant therapy options for resected NSCLC, including chemotherapy, targeted therapy, chemotherapy and immunotherapy. However, which adjuvant therapy is better for which patients is remaining to be explored. With further development of ctDNA-based molecular residual disease (MRD) research, more accurate clinical trials may be needed in the future to refine more comparison of biomarker for more precise treatment in postoperative adjuvant therapy in the future. In our manuscript, we discussed the status of possible markers and possible future clinical trials in combination with MRD. Finer patient stratification and adjuvant treatment options need to be further explored.